RxDoctor Payments Data

Jennifer Jude

Psychiatric/Mental Health · Louisa, KYNPI 1649911819

Payments from drug & device makers

$1,188in general payments, 2019–2025

Across 59 payments — averaging $20.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$395
  • Supernus Pharmaceuticals, Inc.$155
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$150
  • Teva Pharmaceuticals USA, Inc.$113
  • Axsome Therapeutics, Inc.$103
  • Otsuka America Pharmaceutical, Inc.$77
  • plus $196 from 7 others

What the payments were for

  • Food & beverage$1,183100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,188 in reported general payments places this provider in the 60th percentile of 946 psychiatric/mental health providers in Kentucky.

See all psychiatric/mental health providers in Kentucky

Medicare billing

Part B allowed, 2024
$9,247
Medicare patients
39
Services billed
133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine12$81,231
VraylarCariprazine Hcl21$30,556
RexultiBrexpiprazole21$30,084
TrintellixVortioxetine Hydrobromide33$17,070
BelsomraSuvorexant13$5,623
Aripiprazole65$1,157
Hydroxyzine Hcl68$1,013
Quetiapine Fumarate63$974
Clozapine12$958
Clonazepam193$936
Venlafaxine Hcl ErVenlafaxine Hcl51$801
Buspirone Hcl82$652
Duloxetine Hcl99$531
Vilazodone Hcl15$522
Bupropion XlBupropion Hcl68$439

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$113$81,23112 claims
AbbVieVraylar$395$30,55621 claims
Otsuka America Pharmaceutical, Inc.Rexulti$77$30,08421 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$37$17,07033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 946 psychiatric/mental health providers in Kentucky.

Other psychiatric/mental health in Louisa

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →